FI116850B - CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö - Google Patents

CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö Download PDF

Info

Publication number
FI116850B
FI116850B FI941837A FI941837A FI116850B FI 116850 B FI116850 B FI 116850B FI 941837 A FI941837 A FI 941837A FI 941837 A FI941837 A FI 941837A FI 116850 B FI116850 B FI 116850B
Authority
FI
Finland
Prior art keywords
protein
dna
seq
sequence
cells
Prior art date
Application number
FI941837A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941837A0 (fi
FI941837A (fi
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI116850(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI941837A0 publication Critical patent/FI941837A0/fi
Publication of FI941837A publication Critical patent/FI941837A/fi
Application granted granted Critical
Publication of FI116850B publication Critical patent/FI116850B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI941837A 1991-10-25 1994-04-20 CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö FI116850B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US78370791 1991-10-25
US80572391A 1991-12-05 1991-12-05
US80572391 1991-12-05
US9208990 1992-10-23
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
FI941837A0 FI941837A0 (fi) 1994-04-20
FI941837A FI941837A (fi) 1994-05-30
FI116850B true FI116850B (fi) 2006-03-15

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
FI941837A FI116850B (fi) 1991-10-25 1994-04-20 CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö
FI981765A FI116828B (fi) 1991-10-25 1998-08-17 Menetelmä vasta-aineiden valmistamiseksi, jotka ovat immunoreaktiivisia CD40-L-proteiinin kanssa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI981765A FI116828B (fi) 1991-10-25 1998-08-17 Menetelmä vasta-aineiden valmistamiseksi, jotka ovat immunoreaktiivisia CD40-L-proteiinin kanssa

Country Status (13)

Country Link
EP (2) EP0667901B2 (no)
JP (2) JP3308534B2 (no)
KR (1) KR100283541B1 (no)
AT (2) ATE274055T1 (no)
AU (1) AU661360B2 (no)
CA (2) CA2312667C (no)
DE (2) DE69233051T2 (no)
DK (3) DK0822199T3 (no)
ES (2) ES2198025T3 (no)
FI (2) FI116850B (no)
HK (1) HK1019343A1 (no)
NO (2) NO317625B1 (no)
WO (1) WO1993008207A1 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
AU676227B2 (en) * 1993-01-22 1997-03-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
CA2153806C (en) * 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene
CN1137726C (zh) * 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
ATE267607T1 (de) * 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
JP3657271B2 (ja) * 1995-03-01 2005-06-08 イミュネックス・コーポレーション 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
AU693713B2 (en) * 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
CA2224812A1 (en) * 1995-06-22 1997-01-09 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP2000512541A (ja) * 1996-06-14 2000-09-26 ユニバーシティ オブ ワシントン 吸収力が向上した差違抽出装置
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
CA2369820A1 (en) * 1999-04-16 2000-10-26 Frank Dicker Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP3467117B1 (en) 2001-09-20 2020-07-15 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
KR20050101554A (ko) 2003-02-14 2005-10-24 바이오겐 아이덱 엠에이 인코포레이티드 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CN101080487B (zh) 2004-10-07 2012-11-14 阿戈斯治疗公司 成熟树突细胞组合物及其培养方法
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
SG174804A1 (no) 2006-09-13 2011-10-28 Abbott Lab
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PL2214701T3 (pl) 2007-11-01 2017-01-31 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
KR20100113112A (ko) 2008-01-15 2010-10-20 아보트 러보러터리즈 개선된 포유동물 발현 벡터 및 이의 용도
HUE035508T2 (en) 2009-11-17 2018-05-02 Squibb & Sons Llc Procedures for Increased Protein Production
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
KR102007132B1 (ko) 2010-06-09 2019-08-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP2968423A4 (en) 2013-03-15 2016-11-09 Univ Arkansas COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
WO2017024146A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
MX2018013882A (es) 2016-05-11 2019-03-14 Amgen Inc Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa.
EP3585409A4 (en) * 2017-02-27 2020-12-02 Shattuck Labs, Inc. CHEMERICAL PROTEINS BASED ON CSF1R
AU2018223821B2 (en) 2017-02-27 2022-05-19 Shattuck Labs, Inc. TIGIT- and LIGHT-based chimeric proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
NO317625B1 (no) 2004-11-29
CA2121798A1 (en) 1993-04-29
CA2312667C (en) 2002-11-19
FI941837A0 (fi) 1994-04-20
ATE239790T1 (de) 2003-05-15
DK0897983T3 (da) 2003-08-11
HK1019343A1 (en) 2000-02-03
FI981765A (fi) 1998-08-17
NO941422L (no) 1994-06-27
DK0822199T3 (da) 2004-12-27
AU661360B2 (en) 1995-07-20
EP0667901B2 (en) 2008-10-15
FI116828B (fi) 2006-03-15
ES2227513T3 (es) 2005-04-01
DE69233402T2 (de) 2005-09-15
DE69233051D1 (de) 2003-06-12
DK0667901T4 (da) 2008-11-10
EP0667901B1 (en) 2004-08-18
ATE274055T1 (de) 2004-09-15
ES2227513T5 (es) 2009-04-01
JPH07504083A (ja) 1995-05-11
DE69233402D1 (de) 2004-09-23
EP0667901A1 (en) 1995-08-23
WO1993008207A1 (en) 1993-04-29
FI981765A0 (fi) 1998-08-17
EP0897983A3 (en) 1999-03-17
EP0897983A2 (en) 1999-02-24
JP3308534B2 (ja) 2002-07-29
NO980030D0 (no) 1998-01-05
CA2121798C (en) 2007-07-24
JP2877788B2 (ja) 1999-03-31
NO980030L (no) 1998-01-05
NO320073B1 (no) 2005-10-17
DK0667901T3 (da) 2004-12-27
FI941837A (fi) 1994-05-30
EP0897983B1 (en) 2003-05-07
DE69233051T2 (de) 2004-03-11
EP0667901A4 (en) 1995-06-22
NO941422D0 (no) 1994-04-19
CA2312667A1 (en) 1993-04-29
JPH10150994A (ja) 1998-06-09
DE69233402T3 (de) 2009-06-25
KR100283541B1 (ko) 2001-03-02
AU3122693A (en) 1993-05-21
ES2198025T3 (es) 2004-01-16

Similar Documents

Publication Publication Date Title
FI116850B (fi) CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö
US6391637B1 (en) Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
AU693713B2 (en) CD40L mutein
ES2229264T3 (es) Receptor il-17.
DE69132306T2 (de) Menschlicher und Murin-Interleukin-5-Rezeptor
FI103987B (fi) Interleukiini-7
US20040006006A9 (en) CD40-Ligand lacking native-pattern glycosylation
US5726036A (en) Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5925548A (en) Modified receptors that continuously signal
US5629283A (en) Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE
Larson Functional effects of CD40 stimulation on fetal bone marrow B cell precursors: Inhibition or enhancement of growth depending on the developmental stage and the interleukin costimulus

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116850

Country of ref document: FI